Quarterly revenue has held near $1.6B with reported gross margin fluctuating between 6.0% and 15.9% in recent quarters, appearing to reflect cost reclassification rather than underlying pricing power, while net margin remained thin at 2.7% in 2026Q3.
Ardent Health Inc. (ARDT) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 6.45B | 6.32B | 5.97B | 5.41B | 5.13B | 4.16B | 3B | 2.11B |
| Revenue Growth % | 2.03% | 6.01% | 10.29% | 5.45% | 23.25% | 38.63% | 42.6% | - |
| Cost of Goods Sold | 5.18B | 155.7M | 1.03B | 140.84M | 955.17M | 0 | 0 | 0 |
| COGS % of Revenue | - | 2.46% | 17.32% | 2.6% | 18.62% | - | - | - |
| Gross Profit | 1.28B | 6.17B | 4.93B | 5.27B | 4.17B | 4.16B | 3B | 2.11B |
| Gross Margin % | 19.79% | 97.54% | 82.68% | 97.4% | 81.38% | 100% | 100% | 100% |
| Gross Profit Growth % | - | 25.05% | -6.37% | 26.21% | 0.3% | 38.63% | 42.6% | - |
| Operating Expenses | 953.28M | 5.84B | 4.53B | 5.04B | 3.96B | 4.08B | 2.77B | 2.11B |
| OpEx % of Revenue | - | 92.39% | 75.88% | 93.15% | 77.15% | 97.93% | 92.35% | 100% |
| Selling, General & Admin | 376.24M | 1.19B | 3.88B | 3.62B | 3.37B | 2.68B | 1.17B | 1.95B |
| SG&A % of Revenue | - | 18.86% | 65.11% | 66.97% | 65.73% | 64.34% | 38.86% | 92.58% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 15.7M | 19.9M | 0 |
| R&D % of Revenue | - | - | - | - | - | 0.38% | 0.66% | - |
| Other Operating Expenses | 4M | 4.65B | 642.51M | 1.42B | 585.81M | 0 | 0 | 0 |
| Operating Income | 324.21M | 325.58M | 405.76M | 229.5M | 217.03M | 149.76M | 121.77M | 84.75M |
| Operating Margin % | 5.02% | 5.15% | 6.8% | 4.24% | 4.23% | 3.6% | 4.06% | 4.03% |
| Operating Income Growth % | - | -19.76% | 76.8% | 5.75% | 44.92% | 22.98% | 43.68% | - |
| EBITDA | 490.63M | 481.29M | 552.05M | 370.35M | 355.2M | 292.95M | 231.3M | 156.27M |
| EBITDA Margin % | 7.6% | 7.61% | 9.25% | 6.85% | 6.92% | 7.04% | 7.7% | 7.42% |
| EBITDA Growth % | -48.25% | -12.82% | 49.06% | 4.26% | 21.25% | 26.65% | 48.02% | - |
| D&A (Non-Cash Add-back) | 166.42M | 155.7M | 146.29M | 140.84M | 138.17M | 143.19M | 109.53M | 71.51M |
| EBIT | 317.06M | 341.56M | 428.64M | 209.15M | 393.53M | 101.68M | 121.38M | 71.32M |
| Net Interest Income | -51.01M | -55.2M | -65.58M | -65.42M | -82.05M | -108.59M | -70.74M | -26.95M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 51.01M | 55.2M | 65.58M | 65.42M | 82.05M | 108.59M | 70.74M | 26.95M |
| Other Income/Expense | -33.02M | -39.23M | -42.7M | -77.89M | 94.45M | -264.37M | -71.13M | -40.38M |
| Pretax Income | 291.19M | 286.36M | 363.06M | 151.61M | 311.48M | -114.62M | 50.64M | 44.37M |
| Pretax Margin % | 4.51% | 4.53% | 6.09% | 2.8% | 6.07% | -2.75% | 1.69% | 2.11% |
| Income Tax | 60.36M | 56.22M | 63.35M | 22.64M | 46.11M | -11.29M | 49.87M | 8.02M |
| Effective Tax Rate % | 20.73% | 19.63% | 17.45% | 14.93% | 14.8% | 9.85% | 98.47% | 18.08% |
| Net Income | 146.22M | 135.81M | 210.34M | 50.29M | 188.91M | -143.02M | -35.65M | 14.6M |
| Net Margin % | 2.27% | 2.15% | 3.53% | 0.93% | 3.68% | -3.44% | -1.19% | 0.69% |
| Net Income Growth % | -28.69% | -35.43% | 318.24% | -73.38% | 232.08% | -301.21% | -344.15% | - |
| Net Income (Continuing) | 230.83M | 230.13M | 299.71M | 128.98M | 265.37M | -103.33M | 774K | 36.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 385.5M | -1.25M | 390.98M | 411.42M | 411.26M | 380.19M | 382.55M | 129.47M |
| EPS (Diluted) | 1.03 | 0.96 | 1.58 | 0.35 | 1.32 | -1.01 | -0.25 | 0.10 |
| EPS Growth % | -31.33% | -39.24% | 351.43% | -73.48% | 230.69% | -304% | -350% | - |
| EPS (Basic) | - | 0.96 | 1.59 | 0.35 | 1.32 | -1.01 | -0.25 | 0.10 |
| Diluted Shares Outstanding | 141.7M | 141.45M | 132.75M | 143.26M | 143.26M | 140.96M | 140.96M | 140.96M |
| Basic Shares Outstanding | 140.59M | 140.76M | 132.44M | 143.26M | 143.26M | 140.96M | 140.96M | 140.96M |
| Dividend Payout Ratio | - | - | - | - | 92.54% | - | - | - |
Quick answers to the most common questions about buying ARDT stock.
For fiscal year 2025, Ardent Health Inc. (ARDT) reported total revenue of $6.32B. This represents a 200.4% increase compared to $2.11B in 2016.
Ardent Health Inc. (ARDT) is profitable, generating $135.8M in net income for the fiscal year ending 2025 with a net profit margin of 2.1%.
Ardent Health Inc. (ARDT) reported an operating income of $325.6M, resulting in an operating profit margin of 5.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Ardent Health Inc. (ARDT) generated $6.17B in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Margin compression and labor inflation
Metrics are mathematically derived from official filings.
Revenue Plateau Masks Volume Stabilization
Based on reported figures, ARDT's quarterly revenue has held near $1.6B with year-over-year growth decelerating to 2.7% in 2026Q3, suggesting top-line expansion has largely stalled after the 2025 peak.
The revenue series shows a flat trajectory across the last several quarters, with growth swinging between roughly 1% and 4% after reaching 4.4% in 2025Q2. This pattern suggests volume recovery is offsetting limited pricing realization rather than driving meaningful acceleration. Investors should monitor whether same-facility admissions growth of 2.9% can translate into sustained top-line growth or whether payer mix shifts toward government programs cap net revenue per admission.
Reported Gross Margin Reflects Classification Choices
As reported in financial statements, ARDT's gross margin swung from 82.7% to 15.9% across recent quarters, a shift that appears driven by cost reclassification rather than underlying pricing power.
The dramatic gross margin variation, including the drop from 83.6% in 2025Q2 to 42.1% in 2025Q4, indicates that the classification of clinical labor and supply costs between cost of revenue and operating expenses has changed over time. Because of this inconsistency, gross margin is not a reliable standalone indicator for peer comparison. Operating margin, which has ranged from roughly 2.7% to 16.1%, offers a more stable basis, though it remains thin for the sector.
EPS Volatility Diverges From EBITDA Commentary
According to reported earnings, ARDT's diluted EPS fell to $0.31 in 2026Q3 against a $0.35 consensus, while management cited adjusted EBITDA of $138 million, leaving a gap that warrants further investigation.
The disconnect between operational commentary and reported EPS suggests that below-EBITDA items such as depreciation, interest, or non-operating charges may be absorbing operating gains. The negative net income in 2025Q3 against positive operating income of $254.3M further underscores how non-operating items can dominate reported earnings. Investors should examine the reconciliation between adjusted and GAAP figures before drawing conclusions about underlying earnings power.
Labor Expense Discipline Under Scrutiny
Based on ARDT's reported figures, SG&A expense has run between $376M and $1.0B per quarter, and management's cited 4% reduction in salaries, wages, and benefits signals early progress on the labor cost pressures.
Clinical labor appears to be the dominant cost driver, and the reported 4% SWB reduction suggests management is gaining traction on premium contract labor spend. The sharp drop in SG&A from roughly $1.0B to $376M across 2025 likely reflects reclassification rather than pure savings, limiting conclusions about efficiency. Sustained wage discipline will be the key determinant of whether the 5.1% operating margin can expand.
Thin Margins Leave Little Cushion
The strongest bear case is that ARDT's 2.1% net margin, 1.34 debt-to-equity ratio, and 8.5% ROE leave limited room to absorb labor inflation or reductions in government supplemental payments.
Short-side analysis would focus on consecutive EPS misses and the 76.9% year-over-year EPS decline in 2026Q2 as evidence of earnings fragility. If government reimbursement pressure intensifies while wage inflation persists, the thin spread between revenue and earnings could compress further. Investors should monitor whether the reported margin improvements prove durable or are offset by recurring below-the-line charges.